*Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego;
†Division of Hematology-Oncology, University of California, San Diego;
‡Division of Host-Microbe Systems, University of California, San Diego, CA
§Harrison School of Pharmacy, Auburn University, Auburn, AL
¶University of Pittsburgh School of Pharmacy, Pittsburgh, PA
||College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington
Correspondence: Joseph D. Ma, PharmD, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, 9500 Gilman Drive, MC 0657. La Jolla, CA (e-mail: [email protected])
J. Piscitelli was a postdoctoral fellow with funding supported by the Skaggs School of Pharmacy and Pharmaceutical Sciences and Pfizer, Inc. Funding support was provided by a Research in Pediatric and Developmental Pharmacology NIH grant (1U54HD090259-01 to E.V.C.) and a National Center for Complementary and Integrative Health grant (U54 AT008909 to M.F.P.).
The authors declare no conflict of interest.
Part of this work was presented virtually at the 123rd American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 2022.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).
